Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -122.71% is 66% above its 5-year average of -360.05%, near the high end of its 5-year range (-887.06%–-99.36%).
As of the fiscal period ended Tuesday, June 30, 2026. 71.28% above its 12-month average of -427.24%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -122.71%.
RETURN ON EQUITY (ROE)
-122.71%
RETURN ON EQUITY (ROE) AVG TTM
-427.24%
RETURN ON EQUITY (ROE) AVG 3Y
-411.09%
RETURN ON EQUITY (ROE) AVG 5Y
-360.05%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+71.28%
CURRENT VS 3Y AVG
+70.15%
CURRENT VS 5Y AVG
+65.92%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-37.66%
median of 436 covered companies
CURRENT VS SECTOR MEDIAN
-225.84%
vs the sector median at left
Cingulate Inc.
Market Cap
$63.98M
Return on Equity (ROE)
-122.71%
TTM Avg
-427.24%
3Y Avg
-411.09%
5Y Avg
-360.05%
Market Cap
$64.56M
Return on Equity (ROE)
-8.80%
TTM Avg
-13.04%
3Y Avg
-7.69%
5Y Avg
-7.21%
Market Cap
$65.08M
Return on Equity (ROE)
N/A
TTM Avg
-26.44%
3Y Avg
-559.66%
5Y Avg
-417.87%
Market Cap
$61.77M
Return on Equity (ROE)
-76.75%
TTM Avg
-53.49%
3Y Avg
-5.79%
5Y Avg
-19.88%
Market Cap
$66.56M
Return on Equity (ROE)
N/A
TTM Avg
140.07%
3Y Avg
68.30%
5Y Avg
45.41%
Market Cap
$67.11M
Return on Equity (ROE)
N/A
TTM Avg
-285.38%
3Y Avg
-206.98%
5Y Avg
-151.57%
Market Cap
$60.78M
Return on Equity (ROE)
N/A
TTM Avg
71.44%
3Y Avg
1810.59%
5Y Avg
1190.90%
Market Cap
$60.48M
Return on Equity (ROE)
-82.38%
TTM Avg
-68.06%
3Y Avg
-60.95%
5Y Avg
-49.61%
Market Cap
$60.29M
Return on Equity (ROE)
N/A
TTM Avg
-866.00%
3Y Avg
-422.47%
5Y Avg
-312.54%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cingulate Inc. (CING) | $63.98M | -122.71% | -427.24% | -411.09% | -360.05% |
| InterCure Ltd. (INCR)vs › | $64.56M | -8.80% | -13.04% | -7.69% | -7.21% |
| Gossamer Bio, Inc. (GOSS)vs › | $65.08M | N/A | -26.44% | -559.66% | -417.87% |
| Kalaris Therapeutics Inc (KLRS)vs › | $61.77M | -76.75% | -53.49% | -5.79% | -19.88% |
| Alps Group Inc (ALPS)vs › | $66.56M | N/A | 140.07% | 68.30% | 45.41% |
| PDS Biotechnology Corporation (PDSB)vs › | $67.11M | N/A | -285.38% | -206.98% | -151.57% |
| MiNK Therapeutics, Inc. (INKT)vs › | $60.78M | N/A | 71.44% | 1810.59% | 1190.90% |
| Adicet Bio, Inc. (ACET)vs › | $60.48M | -82.38% | -68.06% | -60.95% | -49.61% |
| Fractyl Health, Inc. (GUTS)vs › | $60.29M | N/A | -866.00% | -422.47% | -312.54% |
| Champions Oncology, Inc. (CSBR)vs › | $69.05M | -29.15% | 47.40% | 90.52% | 62.16% |
ROE
-122.7%
ROA
-87.1%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -122.71% |
| 2026-03-31 | -146.91% |
| 2025-12-31 | -887.06% |
| 2025-09-30 | -636.63% |
| 2025-06-30 | -342.88% |
| 2025-03-31 | -292.03% |
| 2024-12-31 | -220.51% |
| 2024-09-30 | -143.24% |
| 2024-06-30 | -619.24% |
| 2024-03-31 | -699.68% |
| 2022-12-31 | -455.34% |
| 2022-09-30 | -187.95% |
| 2022-06-30 | -221.49% |
| 2022-03-31 | -152.20% |
| 2021-12-31 | -99.36% |
| 2021-09-30 | -625.16% |
| 2021-06-30 | -268.55% |
| 2021-03-31 | -471.44% |
| 2020-12-31 | -555.82% |
